Neurotech International Ltd
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company.
The business
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company focuses predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD). In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved. The Company’s subsidiaries include AAT Research Ltd and AAT Medical Ltd.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final visit. The child was the 54th patient to take part in the trial, which recruited individuals between the ages of 8 and 17 […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Neurotech International extends NTI164 Rett Syndrome trial to 52 weeks
Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week duration and was approved by the human research ethics committee at Sydney’s Children’s Hospital at Westmead under clinical trial protocol. A total […]
Neurotech International announces strong results from NTI164 PANDAS/PANS trial extension
Neurotech International (ASX: NTI) has announced “highly significant” improvements during the extension phase of a clinical trial into the impact of its lead candidate NTI164 on children with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and paediatric acute-onset neuropsychiatric syndrome (PANS). NTIPANS1 was the first-ever clinical trial to show improvements in PANDAS/PANS patients […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.